<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03766035</url>
  </required_header>
  <id_info>
    <org_study_id>E7136</org_study_id>
    <nct_id>NCT03766035</nct_id>
  </id_info>
  <brief_title>Cholangioscopy in Primary Sclerosing Cholangitis (PSC)</brief_title>
  <official_title>Cholangioscopy in Primary Sclerosing Cholangitis (PSC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate the clinical utility of the addition of per oral cholangioscopy (POCS) to&#xD;
      standard endoscopic retrograde cholangiopancreatography (ERCP) with brushing cytology for&#xD;
      diagnosis and early detection of cholangiocarcinoma in patients diagnosed with primary&#xD;
      sclerosing cholangitis (PSC).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to demonstrate the clinical utility of the addition of&#xD;
      per oral cholangioscopy (POCS) to standard ERCP with brushing cytology for diagnosis and&#xD;
      early detection of cholangiocarcinoma in patients diagnosed with primary sclerosing&#xD;
      cholangitis (PSC).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 6, 2018</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnostic Accuracy of POCS visualization for Early Detection of Cholangiocarcinoma</measure>
    <time_frame>12 months</time_frame>
    <description>Diagnostic accuracy of POCS visualization for cholangiocarcinoma evaluated clinically at 12 months after initial POCS procedure by clinical presentation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>POCS-guided Biopsy for Early Detection of Cholangiocarcinoma</measure>
    <time_frame>12 months</time_frame>
    <description>Diagnostic accuracy for POCS-guided Biopsy for cholangiocarcinoma evaluated on pathology at 12 months after initial POCS procedure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Technical Success - Ability to advance the scope.</measure>
    <time_frame>Baseline</time_frame>
    <description>Ability to advance the cholangioscope to the target stricture, ability to visualize the stricture and ability to obtain a tissue sample with Spy Bite where applicable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Adverse Events</measure>
    <time_frame>From index through study completion, an average of one year</time_frame>
    <description>Serious adverse events from initial POCS procedure until end of follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients identified for repeat procedure.</measure>
    <time_frame>During index procedure</time_frame>
    <description>Proportion of patients identified for repeat procedure considering the addition of Spy Glass DS visualization and Spy Bite biopsy at Index compared to the proportion identified for repeat procedure without consideration of Spy Glass DS visualization and Spy Bite biopsy at Index.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correspondence of Biopsies</measure>
    <time_frame>From index through study completion, an average of one year</time_frame>
    <description>Correlation between histopathology of Spy Bite biopsies collected during the initial POCS procedure and final diagnosis.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">105</enrollment>
  <condition>Primary Sclerosing Cholangitis (PSC)</condition>
  <arm_group>
    <arm_group_label>Consented, enrolled PSC patients undergoing ERCP + SpyGlass</arm_group_label>
    <description>Patients with PSC who have been consented and enrolled in the study will undergo ERCP with the addition of SpyGlass as indicated by their treating physician.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SpyGlass DS I - II</intervention_name>
    <description>The SpyScope™ DS Access and Delivery Catheter (SpyScope™ DS Catheter) is a sterile, single-use endoscope that enables access and delivery of accessories to targeted pancreaticobiliary anatomy and displays live video when connected to a Spy Glass DS Digital Controller.</description>
    <arm_group_label>Consented, enrolled PSC patients undergoing ERCP + SpyGlass</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum collection&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed with PSC&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Confirmed diagnosis of PSC&#xD;
&#xD;
          2. Clinical indication for ERCP per local standard of practice, such as suspicion of&#xD;
             potential malignancy based on worsening cholestatic values or clinical presentation&#xD;
             (such as itching, cholangitis) or new biliary stricture on trans-abdominal imaging&#xD;
             (MRI/MRCP, US or CT) or suspicious cytology&#xD;
&#xD;
          3. Diameter of bile ducts deemed sufficient to accommodate the cholangioscopy system&#xD;
             based on imaging performed prior to scheduled ERCP&#xD;
&#xD;
          4. Written informed consent from patient to participate in the study, including&#xD;
             compliance with study procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Contraindication for an ERCP or POCS&#xD;
&#xD;
          2. History of liver transplantation&#xD;
&#xD;
          3. Mass/metastasis extrinsic to the bile duct identifiable on diagnostic imaging&#xD;
&#xD;
          4. History of iatrogenic bile duct trauma, including biliary surgery within 6 months of&#xD;
             enrollment&#xD;
&#xD;
          5. INR &gt; 1.5 or platelets count &lt; 50,000&#xD;
&#xD;
          6. Age &lt; 18 years&#xD;
&#xD;
          7. Pregnant women or women trying to become pregnant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johannes Eksteen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aspen Woods Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Douglas Adler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Utah Hospital and Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lars Aabakken, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rikshospitalet Oslo University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cyriel Ponsioen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sooraj Tejaswi, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sutter Davis Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christopher Bowlus, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UC Davis Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Danielle Vannan, PhD</last_name>
    <phone>508-683-4139</phone>
    <email>Danielle.Vannan@bsci.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Srey Yin</last_name>
    <phone>508-683-4162</phone>
    <email>Srey.Yin@bsci.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sutter Davis Hospital</name>
      <address>
        <city>Davis</city>
        <state>California</state>
        <zip>95616</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sooraj Tejaswi, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UC Davis Health</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Bowlus, MD, PhD</last_name>
    </contact>
    <contact_backup>
      <last_name>Shiro Urayama, MD, PhD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Utah Hospital and Clinic</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Aspen Woods Clinic</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T3H 0V5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joni Tsougrianis</last_name>
      <email>research@aspenwoodsclinic.com</email>
    </contact>
    <investigator>
      <last_name>Johannes Eksteen, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rachid Mohamed, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nauzer Forbes, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Academic Medical Center</name>
      <address>
        <city>Amsterdam-Zuidoost</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Cyriel Ponsioen, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rikshospitalet University Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>0372</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Siv Furholm</last_name>
      <email>siv.furholm@ous-hf.no</email>
    </contact>
    <investigator>
      <last_name>Lars Aabakken, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vemund Paulsen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Finland</country>
    <country>Sweden</country>
  </removed_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 8, 2018</study_first_submitted>
  <study_first_submitted_qc>December 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 5, 2018</study_first_posted>
  <last_update_submitted>November 18, 2021</last_update_submitted>
  <last_update_submitted_qc>November 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>per oral cholangioscopy</keyword>
  <keyword>PSC</keyword>
  <keyword>cholangiocarcinoma</keyword>
  <keyword>primary sclerosing cholangitis</keyword>
  <keyword>ERCP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangitis</mesh_term>
    <mesh_term>Cholangitis, Sclerosing</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

